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Introduction: Breast cancer is the second leading cause of cancer death in women worldwide and the third most
common cancer in India. Various studies have reported that chemotherapy reduces the antioxidant status in patients
with cancer. A diet rich in omega-3 fatty acids has been shown to offer protection against breast cancer through
various mechanisms. However, there are no reports suggesting a relationship between consumption of omega-3
fatty acids during chemotherapy and antioxidant status in patients with breast cancer. Thus, the objective of this
study was to evaluate whether fish oil supplementation could improve the antioxidant status of five women with
breast cancer undergoing chemotherapy.
Case presentation: We report on the cases of five Indian women with breast cancer, in the age group of 34 to 60
years, who had poorly differentiated breast carcinoma and underwent modified radical mastectomy. Postsurgery,
the patients were given fish oil capsules containing eicosapentaenoic acid (180mg) and docosahexaenoic acid
(120mg)/capsule during their chemotherapy. Informed consent was obtained from each participant and they were
followed-up to the completion of six chemotherapy cycles at 21-day intervals.
Conclusions: The supplementation of fish oil significantly (p < 0.01) increased superoxide dismutases, glutathione
reductase and catalase activity in red blood cells as well as the total plasma antioxidant status in the patients. This
approach of using omega-3 fatty acids as an adjuvant treatment for breast cancer may help oncologists to manage the
side effects of ongoing chemotherapy by improving the antioxidant status in patients.
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Breast cancer is the third most common cancer in
Indian women, followed by cervical and stomach cancers
[1]. The role of nutrition in the prevention of cancer has
been recently established based on the available epi-
demiological data. Dietary agents have been shown to
suppress the transformative, hyperproliferative and in-
flammatory processes that initiate carcinogenesis [2].
Dietary fatty acids have been shown to play an import-
ant role not only in normal growth and development but
also in the treatment of cancer and other diseases [3, 4].
Various studies have reported the anti-cancer activity
of omega-3 polyunsaturated fatty acids (n-3 PUFAs),* Correspondence: ruchika.kaulghanekar@gmail.com
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creativecommons.org/publicdomain/zero/1.0/eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), usually found in cold water fish. Clinical studies
have shown that these fatty acids benefitted patients
with cancer by; increasing their response to chemother-
apy; lowering the side effects of chemotherapy; increas-
ing survival; improving quality of life (QoL); reducing
hospital stay and severity of postoperative infections;
and improving appetite, body weight, nutrition and clin-
ical performance parameters such as liver and pancreas
function [4–7]. EPA and DHA have been reported to
improve the therapeutic index of chemotherapeutic
drugs such as anthracyclines, purine and pyrimidine
analogues, alkylating agents, cisplatin and vinca alkaloids
by either increasing their efficacy and/or reducing their
toxicity in different cancers, including breast cancer [5, 8].article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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(FO) by patients with breast cancer undergoing chemo-
therapy on their antioxidant status has not been explored.
Case presentation
The present study was carried out at our hospital, 2
years ago for a period of 1 year and 9 months and was
approved by the Institutional Ethical Committee. In-
formed consent was obtained from all the participants in
the study. The patients were negative for human immu-
nodeficiency virus, hepatitis, pancreatitis, iron deficiency
anemia or renal disease. All the patients underwent
standard preoperative malignancy investigations including
mammography, ultrasound examination and fine needle
aspiration cytology (FNAC) of the lesion. The results
showed poorly differentiated breast carcinoma in the
patients who were subsequently advised for modified
radical mastectomy (MRM). Preoperative X-ray chest
posterior-anterior (PA) view and ultrasonography (USG)
scan of the abdomen showed no distant metastasis at the
time of admission. No episodes of bleeding, failure of
sutures, infection or death were reported after surgery.
The patients were followed-up during the entire course
of six chemotherapy cycles. Patients were given FO
during chemotherapy in the form of Mega-3™ capsules
(Dr. Reddy’s Laboratories), containing EPA (180mg) and
DHA (120mg)/capsule. Since we wanted to evaluate the
antioxidant potential of only FO, we selected Mega-3™
capsules as they did not contain any other component,
particularly antioxidants. The dose for each patient was
decided by the physician based on the grade of the
cancer and the patient’s overall clinical condition. For
Cases 2 to 5, six capsules per day were given and for
Case 1, four capsules per day were given. The dosage in
all the cases did not exceed more than 2 g per day and
was according to US Food and Drug Administration
recommendations [9].
Brief details of each case are presented below and the
patients’ characteristics are summarized in Table 1.
Case 1
Case 1 is an Indian woman who has been a tobacco user
since the age of 12; her family history did not show any
type of malignancy in her first degree relatives. She com-
plained of a lump in her left breast which was painless,
mobile and persistent in size. No significant surgical his-
tory was reported and she had normal weight as per her
body mass index (BMI). On clinical examination, a hard
lump was palpated in the upper medial quadrant of her
left breast. Axillary lymph nodes were free of tumor.
Case 2
Case 2 is an Indian woman was admitted with the chief
complaint of a left breast lump persisting for 2 months,which had caused her pain for the last 15 to 20 days.
She has been a tobacco user since the age of 15. She had
a past medical history indicating bronchial asthma and
had undergone lumpectomy approximately 8 years ago.
She did not have any family history of cancer and had
normal weight as per her BMI. She had osteopenia and
high serum alkaline phosphatase (ALP) levels at the time
of admission to our hospital. She was diagnosed with
infiltrating ductal carcinoma.
Case 3
Case 3 is an Indian woman who was admitted with the
chief complaint of a right breast lump persisting for the
last 2 months. It had caused her pain for the month
before admission to our hospital and showed tenderness
upon touch. No nipple discharge was observed. She has
been a tobacco user since the age of 35. She had a past
medical history of hysterectomy, approximately 30 years
ago and had hypertension. She was a known case of
rheumatic heart disease. She did not have any personal
or family history of cancer and was overweight as per
her BMI. She was diagnosed with infiltrating ductal car-
cinoma. She was reported to have decreased appetite
upon admission.
Case 4
Case 4 is an Indian woman who was admitted with the
chief complaint of a right breast lump persisting for 6
months which was painless and had gradually increased
in size. She had a past medical history of oophorectomy
and had hypertension for 1 year. She did not have any
family history of cancer and was underweight as per her
BMI. She was reported to have decreased appetite and
low hemoglobin at the time of admission. She was diag-
nosed with infiltrating ductal carcinoma.
Case 5
Case 5 is an Indian woman who was admitted with the
chief complaint of a left breast lump persisting for 2 to 3
months that was associated with nipple inversion. She
had been a tobacco user since the age of 20. She did not
have any family history of cancer. She belonged to obese
class I as per her BMI and had been diagnosed with in-
filtrating ductal carcinoma.
We collected venous blood from all the five patients
after surgery (but before chemotherapy and FO supple-
mentation) and after every cycle of chemotherapy (during
FO supplementation) in ethylenediaminetetraacetic acid
(EDTA) coated vials. The blood was immediately layered
onto the histopaque column (Sigma-Aldrich) and cen-
trifuged at 400 × g for 35min to separate the red blood
cells (RBCs) and plasma fractions. RBCs were washed
with saline and together with plasma were stored at −80 °C
until further analysis. The blood samples were analyzed for
Table 1 Clinical characteristics of the patients with breast cancer
Patient Case 1 Case 2 Case 3 Case 4 Case 5
Age (years) 34 60 51 59 45
BMI 23.7 19.6 25.1 17.8 30.7
Age at first period
(years)
14 15 15 13 14
Age at first birth
(years)
18 17 17 18 18
ECOG score [21] 1 3 2 2 3
Preoperative lump
size (cm)
4 × 3 5 × 3 6 × 4 4 × 2 10 × 8
TNM Stage T1N0MX T4N0M0 T2N1M0 T2N0M0 T2N2MX
ER Negative Positive (80 %) Positive (90 %) Positive (80 %) Negative
PR Negative Positive (80 %) Positive (85 %) Negative Negative
HER2 Positive (score: 3+) Negative Negative Negative Positive (score: 3+)
Fish oil dosage
(gm/day)
1.2 1.8 1.8 1.8 1.8
No. of days of fish
oil supplementation
130 130 188a 136 132
No. of capsules per
day





















BMI body mass index, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor













Mansara et al. Journal of Medical Case Reports  (2015) 9:148 Page 4 of 6the status of antioxidant enzymes (SOD, CAT and GRx) in
RBCs and total antioxidant status in plasma. SOD (EC
1.15.1.1), CAT (EC 1.11.1.6) and GRx (EC 1.6.4.2) were
estimated by using commercially available kits (Cayman,
Michigan, USA). Total plasma antioxidants were mea-
sured by oxygen radical absorbance capacity (ORAC)
assay as described previously [10]. Patients filled out a
self-administered European Organisation for Research
and Treatment of Cancer (EORTC) QLQ-C30 [11]
questionnaire before chemotherapy as well as after
chemotherapy and FO supplementation. It is a multidi-
mensional validated cancer-specific measure that in-
cludes global health status and QoL, functional and
symptom scales. EORTC QLQ-C30 subscales were
calculated according to the EORTC-QLQ manual and
vary from 0 to 100. A high score for a functional or QoL
scale represents high level of functioning or QoL. A
high score for a symptom scale represents high level of
problems. Statistical analysis was performed by using
GraphPad Prism 5. The results were plotted after aver-
aging out the data from all the chemotherapy cycles
(after FO supplementation) for each patient and then
plotted as a cumulative mean of the data obtained from
all the five patients. All the results have been presented
as mean ± standard deviation. The data was analyzed by
using a two-tailed paired t test to compare the effect of
FO intervention on antioxidant enzymes and total anti-
oxidant status before and after supplementation, with a
significance level of 0.05.Fig. 1 Fish oil supplementation improves the antioxidant status in five pati
(b) and glutathione reductase (GRx) (c) activities in red blood cells and plasma
and fish oil supplementation (Chemo + FO) have been shown. The results
indicates statistically significant difference in the results before and after fResults
The clinical characteristics of each patient including
age, BMI and other parameters have been summarized
in Table 1. The patients showed a significant increase
(p < 0.01) in SOD, CAT and GRx levels in the RBC frac-
tions after FO supplementation as compared to the
values obtained before chemotherapy and FO supple-
mentation (Fig. 1a–c).
We also evaluated the total antioxidant status in the
plasma samples of all the patients by ORAC. The assay is
based on the inhibition of free radical production from the
2,2′-azobis (2-amidinopropane) dihydrochloride (AAPH)
substrate by the antioxidant molecules present in the test
sample. It can determine both hydrophilic and lipophilic
antioxidants, which represent the total antioxidant cap-
acity. All the patients showed a significant increase in
ORAC values (p < 0.01) after omega-3 fatty acid supple-
mentation (Fig. 1d).
Discussion
Various studies have reported a decrease in antioxidant
levels and an increase in reactive oxygen species (ROS) in
patients with breast cancer post-chemotherapy [12, 13].
Such reduced antioxidant status and enhanced ROS often
lead to various side effects such as nephrotoxicity, cardio-
toxicity and peripheral neuropathy that hamper tumor
treatment and may even lead to a patient’s death. The
antioxidant enzymes such as SOD, GPx and CAT work
together in human cells to remove the toxic ROS.ents with breast cancer. Superoxide dismutase (SOD) (a), catalase (CAT)
antioxidant status (d) in the patients before and after chemotherapy
have been presented as mean ± standard deviation. **p < 0.01
ish oil intervention. ORAC oxygen radical absorbance capacity
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in the modulation of antioxidant status has not been prop-
erly evaluated at the clinical level. In our study, all the
patients were found to show significant improvement in
their antioxidant status in RBC and plasma fractions after
FO supplementation.
Recently, nutrition has become one of the most import-
ant aspects in cancer management. Reduced nutrition and
subsequent poor health lowers antioxidant status, which
may be associated with increased neoplastic activity in
patients with cancer [14, 15]. An antioxidant rich diet has
been shown to enhance the chemotherapy response and
improve the QoL in patients by minimizing the side
effects of chemotherapeutic drugs [14, 15]. Supplemen-
tation of vitamins C and/or E before and after breast
cancer diagnosis, as well as radiation and hormone ther-
apy, has been shown to protect against chemotherapy-
related side effects through an increase in SOD, CAT,
glutathione (GSH) and GRx and a decrease in the levels
of malondialdehyde and DNA damage [15]. Similarly,
the Shanghai Breast Cancer Survival Study has indicated
that supplementation of vitamins E, C or multivitamins
within 6 months of breast cancer diagnosis correlated
with a decrease in recurrence rate and mortality [16].
Such supplementation may also alleviate dose-limiting
toxicities which would help patients to complete the
prescribed chemotherapy regimens resulting in better
management of cancer.
The rationale behind supplementation of EPA and DHA
in patients with breast cancer was laid down by various
cross-sectional studies, which showed that higher intake
of these fatty acids was associated with decreased risk ofTable 2 Fish oil supplementation improved quality of life in five pat
Before chemotherapy
EORTC QLQ-C30 Global health score 46.67 ± 5.00
EORTC QLQ-C30 Functional scales
Physical functioning score 48.00 ± 3.89
Role functioning score 46.67 ± 8.17
Emotional functioning score 10.00 ± 3.12
Cognitive functioning score 80.00 ± 6.24
Social functioning score 33.33 ± 5.27
EORTC QLQ-C30 Symptom scales
Fatigue score 62.22 ± 10.31
Nausea and vomiting score 30.00 ± 8.16
Pain score 56.67 ± 8.50
Dyspnoea score 53.33 ± 8.17
Insomnia score 53.33 ± 8.17
Appetite loss score 93.33 ± 6.67
Financial difficulties score 80.00 ± 13.33
EORTC European Organisation for Research and Treatment of Cancer, ns nonsignificcancer-related mortality [17]. Other studies have shown
that omega-3 fatty acids from fish/shell fish could decrease
the risk of breast cancer and adverse events related to it
[18]. FO supplementation has been shown to: reduce
malignant epithelial cell proliferation (Ki67) marker in
prostate cancer; reverse cachexia in advanced pancreatic
cancer; maintain patient weight and muscle mass during
chemotherapy in lung cancer; improve liver and pan-
creas function in postoperative patients with abdominal
cancer; and increase chemotherapeutic efficacy (without
affecting the toxicity profile) and survival in patients
with lung cancer [5–8, 19]. Based on the EORTC ques-
tionnaire, after chemotherapy and FO supplementation,
patients showed improved QoL scores compared to that
observed before chemotherapy (Table 2). The patients
showed significant improvement in global health status
after supplementation of FO during chemotherapy.
Global health status is an indication of a patient’s own
judgment of health status and QoL [20]. The functional
status scales that included physical, emotional and social
functioning were found to be significantly improved after
chemotherapy and FO supplementation. The patients
showed significant reduction in fatigue, pain and appetite
loss scale after receiving FO during chemotherapy. Other
functional or symptom scales of EORTC QLQ-C30 did
not differ significantly before chemotherapy and after
chemotherapy and FO supplementation.
Conclusions
The supplementation of FO containing omega-3 fatty
acids, EPA and DHA, benefitted patients with breast
cancer by increasing their antioxidant levels. Theseients with breast cancer
After chemotherapy and fish oil supplementation P value
86.67 ± 3.33 <0.001
77.33 ± 2.67 <0.001
80.00 ± 8.16 ns
53.33 ± 6.77 <0.001
80.00 ± 8.16 ns
66.67 ± 10.54 <0.001
26.66 ± 6.67 <0.001
10.00 ± 4.08 ns
23.33 ± 8.50 <0.001
26.67 ± 12.47 ns
33.33 ± 0.00 ns
26.66 ± 6.67 <0.001
73.33 ± 12.47 ns
ant
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adequate randomized study to elucidate its possible role
as an adjuvant in the management of breast cancer.
Consent
Written informed consent was obtained from the patients
for publication of this case series. Copies of the written
consents are available for review by the Editor-in-Chief of
this journal.
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